ChemoCentryx (CCXI) to Present Positive CCX168 Phase 2 Data at ASN Kidney Week 2016
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
ChemoCentryx, Inc., (Nasdaq: CCXI) announced that positive data from an ongoing Phase II proof-of-concept study of CCX168 for the treatment of Atypical Hemolytic Uremic Syndrome (aHUS) will be presented at the American Society of Nephrology (ASN) Kidney Week 2016 Annual Meeting. CCX168 (newly designated “avacopan”) is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. CCX168 (avacopan) is a lead drug candidate in the Company's orphan and rare disease program.
The data to be presented are from the Company’s ongoing open-label clinical study designed to assess the effects of orally-administered CCX168 on thrombus formation ex vivo from aHUS patients with end-stage renal disease. The aHUS patients in the study are on stable chronic hemodialysis or peritoneal dialysis and CCX168 (avacopan) treatment to these patients comprised administration of the agent at 30 mg twice daily for two weeks. Five patients have been treated to date. Highlights from the presentation will include the following:
- After 14 days of dosing in aHUS patients, the mean decrease in thrombus size was 83%. Three patients showed 100% inhibition of thrombus formation and one patient showed >30% inhibition. Additionally, one patient who received only two days of treatment showed >30% inhibition at that time.
- Treatment appeared to be mechanism specific: when CCX168 treatment was stopped, the thrombus size returned to baseline levels.
- Not unexpectedly, serum C3, C4, and plasma C5b-9 levels were unchanged with CCX168 treatment.
- There was one SAE, not considered related to CCX168 use, in a patient with long-standing cardiovascular and renal disease of cardiac asystole.
- Patients with aHUS often have low platelet counts due to high thrombotic activity. Two patients in the study had low platelet counts which increased on CCX168 treatment (163 to 223/μL and 152 to 196/μL).
“Atypical hemolytic uremic syndrome, or aHUS, is a rare, life-threatening disease characterized by systemic thrombotic microangiopathy (TMA), or the formation of blood clots in small blood vessels, throughout the body,” said Giuseppe Remuzzi, M.D., F.R.C.P., Head of Nephrology and Dialysis and Chairman of the Department of Transplantation at Bergamo Hospital and Research Coordinator of Mario Negri Institute for Pharmacological Research in Bergamo, Italy. “We are especially encouraged to find that with CCX168 treatment a complete inhibition of thrombus formation induced by the serum of three aHUS patients on microvascular endothelium, as well as partial inhibition in the other two patients evaluated to date. This is particularly important, as systemic TMA can lead to heart attack, stroke, and kidney failure, which are the primary causes of mortality associated with aHUS.”
“People with aHUS have a lifelong risk of having this devastating condition suddenly become active. We believe that inhibition of the C5a receptor by CCX168 represents a potential solution to preventing ischemic end-organ damage in these patients,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer, ChemoCentryx. “We look forward to initiating a multi-center clinical trial in patients with aHUS in 2017.”
The results will be presented in a poster titled, “Orally Administered Complement 5a Receptor Inhibitor CCX168 Shows Ex Vivo Anti-Thrombogenic Activity in a Phase 2 Study in End-Stage Renal Disease Patients with Atypical Hemolytic Uremic Syndrome (ACCESS Study) (Abstract #1975, November 17, 10:00 to 2:00 p.m. CT, Session: CKD: Clinical Trials).
Other company presentations at ASN Kidney Week 2016 include:
|Oral:||Rapid Onset of Action of Orally Administered C5aR Inhibitor CCX168 in Randomized Clinical Trial in ANCA-Associated Vasculitis (CLEAR) Abstract Program #TH-OR037|
|Presenter:||Dr. David Jayne, Director, Vasculitis and Lupus Clinic, the University of Cambridge, UK and Principal Investigator of the CLEAR trial|
|Session:||CKD and AKI Clinical Trials|
|Date & Time:||Thursday, 11/17/2016, 4:30 PM - 6:30 PM CT|
|Poster:||Creation of Complement Factor H Mutations in human C5a-Receptor Knock-in Mice as a Model to Assess the Effects of C5aR Antagonism in Complement-Mediated Renal Diseases (Abstract #1945)|
|Presenter:||Chris Li, Senior Scientist, ChemoCentryx|
|Session:||Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases|
|Date & Time:||Friday, 11/18/2016, 10:00 AM - 12:00 PM CT|
The abstracts can be accessed through the ASN Kidney Week 2016 website. Following the meeting, copies of the posters can be obtained by contacting the Company.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Commences KRN23 Phase 3 in XLH
- Moleculin Biotech (MBRX) Advances WP1122 into Preclinical Stage
- Dynavax (DVAX) Announces Significant Subgroup Data from HEPLISAV-B Phase 3
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!